Israel - English - Ministry of Health

novartis israel ltd - epoetin alfa - solution for injection - epoetin alfa 3000 iu / 0.3 ml - erythropoietin - erythropoietin - binocrit® is indicated for the treatment of symptomatic anaemia associated with chronic renal failure (crf):- in adults and children aged 1 to 18 years on haemodialysis and adult patients on peritoneal dialysis .- in adults with renal insufficiency not yet undergoing dialysis for the treatment of severe anaemia of renal origin accompanied by clinical symptoms in patients. binocrit® is indicated in adult patients receiving chemotherapy for solid tumours, malignant lymphoma or multiple myeloma, and at risk of transfusion as assessed by the patient's general status (e.g. cardiovascular status, pre existing anaemia at the start of chemotherapy) for the treatment of anaemia and reduction of transfusion requirements.binocrit® is indicated in adults in a predonation programme to increase the yield of autologous blood.treatment should only be given to patients with moderate anaemia (haemoglobin (hb) concentration range between 10 13 g/dl (6.2 8.1 mmol/l), no iron deficiency), if blood saving procedures are not available or insufficient when the scheduled major elective surgery requires a large volume of blood (4 or more units of blood for females or 5 or more units for males).binocrit® is indicated for non-iron deficient adults prior to major elective orthopaedic surgery, having a high perceived risk for transfusion complications to reduce exposure to allogeneic blood transfusions.use should be restricted to patients with moderate anaemia (e.g. hb concentration range between 10 13 g/dl or 6.2 8.1 mmol/l) who do not have an autologous predonation programme available and with an expected blood loss (900 to 1800 ml).

Israel - English - Ministry of Health

novartis israel ltd - epoetin alfa - solution for injection - epoetin alfa 40000 iu / 1 ml - erythropoietin - erythropoietin - binocrit® is indicated for the treatment of symptomatic anaemia associated with chronic renal failure (crf):- in adults and children aged 1 to 18 years on haemodialysis and adult patients on peritoneal dialysis .- in adults with renal insufficiency not yet undergoing dialysis for the treatment of severe anaemia of renal origin accompanied by clinical symptoms in patients. binocrit® is indicated in adult patients receiving chemotherapy for solid tumours, malignant lymphoma or multiple myeloma, and at risk of transfusion as assessed by the patient's general status (e.g. cardiovascular status, pre existing anaemia at the start of chemotherapy) for the treatment of anaemia and reduction of transfusion requirements.binocrit® is indicated in adults in a predonation programme to increase the yield of autologous blood.treatment should only be given to patients with moderate anaemia (haemoglobin (hb) concentration range between 10 13 g/dl (6.2 8.1 mmol/l), no iron deficiency), if blood saving procedures are not available or insufficient when the scheduled major elective surgery requires a large volume of blood (4 or more units of blood for females or 5 or more units for males).binocrit® is indicated for non-iron deficient adults prior to major elective orthopaedic surgery, having a high perceived risk for transfusion complications to reduce exposure to allogeneic blood transfusions.use should be restricted to patients with moderate anaemia (e.g. hb concentration range between 10 13 g/dl or 6.2 8.1 mmol/l) who do not have an autologous predonation programme available and with an expected blood loss (900 to 1800 ml).

Israel - English - Ministry of Health

tzamal bio-pharma ltd - candesartan cilexetil - tablets - candesartan cilexetil 4 mg - candesartan - candesartan - hypertension. treatment of patients with heart failure and impaired left ventricle systolic function ( left ventricular ejection fraction < or = 40 % ) as add-on therapy to ace inhibitors or when ace inhibitors are not tolerated.

Israel - English - Ministry of Health

tzamal bio-pharma ltd - candesartan cilexetil - tablets - candesartan cilexetil 8 mg - candesartan - candesartan - hypertension. treatment of patients with heart failure and impaired left ventricle systolic function ( left ventricular ejection fraction < or = 40 % ) as add-on therapy to ace inhibitors or when ace inhibitors are not tolerated.

Israel - English - Ministry of Health

tzamal bio-pharma ltd - candesartan cilexetil - tablets - candesartan cilexetil 16 mg - candesartan - candesartan - hypertension. treatment of patients with heart failure and impaired left ventricle systolic function ( left ventricular ejection fraction < or = 40 % ) as add-on therapy to ace inhibitors or when ace inhibitors are not tolerated.

Israel - English - Ministry of Health

tzamal bio-pharma ltd - urofollitropin - powder for solution for injection - urofollitropin 75 iu/vial - urofollitropin - urofollitropin - a treatment with fsh followed by the administration of human chronic gonadotrophin (hcg) is indicated to induce ovulation in infertile women suffering from hypothalamus or hypophyseal disorders and in spanomenorrhoeic or amenorrhoeic women. these women belong to the who group ii and have generally already been treated with clomiphene citrate. most have polycystic ovarian syndrome. fsh offers good therapeutic prospects for patients whose lh:fsh ratio has to be adjusted, avoiding an exogenous supply of lh fsh may be used alone or in concomitance with human menopausal gonadotropin (hmg) in order to stimulate multiple follicular growth in patients involved in medically assisted reproduction programs (ivf-et,gift).

Israel - English - Ministry of Health

tzamal bio-pharma ltd - urofollitropin - powder for solution for injection - urofollitropin 150 iu/vial - urofollitropin - urofollitropin - a treatment with fsh followed by the administration of human chronic gonadotrophin (hcg) is indicated to induce ovulation in infertile women suffering from hypothalamus or hypophyseal disorders and in spanomenorrhoeic or amenorrhoeic women. these women belong to the who group ii and have generally already been treated with clomiphene citrate. most have polycystic ovarian syndrome. fsh offers good therapeutic prospects for patients whose lh:fsh ratio has to be adjusted, avoiding an exogenous supply of lh fsh may be used alone or in concomitance with human menopausal gonadotropin (hmg) in order to stimulate multiple follicular growth in patients involved in medically assisted reproduction programs (ivf-et,gift).

Israel - English - Ministry of Health

tzamal bio-pharma ltd - dacarbazine as citrate - powder for solution for inj/inf - dacarbazine as citrate 200 mg/vial - dacarbazine - dacarbazine - decarbazine is indicated for the treatment of patients with metastatic malignant melanoma. further indications for dacarbazine as part of a combination chemotherapy in advanced hodgkin's disease as a second line.

Israel - English - Ministry of Health

tzamal bio-pharma ltd - dacarbazine as citrate - powder for solution for inj/inf - dacarbazine as citrate 500 mg/vial - dacarbazine - dacarbazine - decarbazine is indicated for the treatment of patients with metastatic malignant melanoma. further indications for dacarbazine as part of a combination chemotherapy in advanced hodgkin's disease as a second line.

Israel - English - Ministry of Health

tzamal bio-pharma ltd - dacarbazine as citrate - powder for solution for inj/inf - dacarbazine as citrate 1000 mg/vial - dacarbazine - dacarbazine - decarbazine is indicated for the treatment of patients with metastatic malignant melanoma. further indications for dacarbazine as part of a combination chemotherapy in advanced hodgkin's disease as a second line.